Related Experiment Video
Updated: Feb 28, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Monitoring of treatment for metastatic castration-resistant prostate cancer]
Abstract:
Treatments currently available for metastatic castration-resistant prostate cancer (mCRPC) include abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, and radium-223. However, the optimal sequence of these agents is still unclear, and markers to predict treatment response and facilitate patient selection remain an unmet need. In terms of overall survival, it is crucial that patients receive all treatment options currently available. This requires early detection of progression as an indication for a treatment switch. In this context, a structured monitoring of treatment is important in clinical practice.
Insights
Optimal sequencing of treatments for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Early detection of progression is crucial for timely treatment switches to improve overall survival in mCRPC patients.
Area of Science:
- Oncology
- Medical treatment
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) has several treatment options including abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, and radium-223.
- The optimal sequence for administering these therapies remains undetermined.
- Predictive markers for treatment response and patient selection are currently lacking.
Purpose of the Study:
- To highlight the importance of structured treatment monitoring in clinical practice.
- To emphasize the need for early progression detection to guide treatment switching.
- To underscore the goal of ensuring patients receive all available treatment options for improved overall survival.
Main Methods:
- This study is a review and discussion of current treatment strategies for mCRPC.
- Focuses on the clinical implications of treatment sequencing and monitoring.
- No new experimental data was generated.
Main Results:
- Current treatment options for mCRPC are listed.
- The lack of clear sequencing guidelines and predictive markers is identified as a significant unmet need.
- The critical role of early progression detection for treatment modification is emphasized.
Conclusions:
- Ensuring patients receive all available therapies is vital for maximizing overall survival in mCRPC.
- Structured monitoring and early detection of disease progression are essential for effective clinical management.
- Further research is needed to establish optimal treatment sequences and identify predictive biomarkers.
